SONOSCAPE(SZ:300633) Sou Hu Cai Jing·2025-12-31 15:07Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with a slight increase in revenue but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of December 31, 2025, Kaili Medical's stock closed at 26.42 yuan, up 0.84%, with a turnover rate of 0.92% and a trading volume of 40,000 hands, amounting to a transaction value of 105 million yuan [1]. - On December 31, the net inflow of main funds was 15.99 million yuan, accounting for 15.25% of the total transaction value, while retail funds saw a net outflow of 5.25 million yuan, representing 5.01% of the total transaction value [1]. Analyst Ratings - In the last 90 days, 11 institutions have provided ratings for Kaili Medical, with 9 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].